Lajos Pusztai

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Linda J Adepoju
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:42-50. 2006
  2. ncbi request reprint Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Cancer Invest 22:248-56. 2004
  3. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
  4. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
  5. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
  6. ncbi request reprint Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:5678-85. 2005
  7. doi request reprint Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030 1439, USA
    Breast Cancer Res Treat 121:301-9. 2010
  8. pmc Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
  9. ncbi request reprint Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
  10. doi request reprint Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010

Collaborators

Detail Information

Publications94

  1. ncbi request reprint Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Linda J Adepoju
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:42-50. 2006
    ....
  2. ncbi request reprint Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Cancer Invest 22:248-56. 2004
    ..However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy...
  3. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  4. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  5. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  6. ncbi request reprint Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy...
  7. doi request reprint Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030 1439, USA
    Breast Cancer Res Treat 121:301-9. 2010
    ..Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients...
  8. pmc Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
    ..Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined...
  9. ncbi request reprint Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
    ..The authors also compared the plasma profiles of patients with cancer with the plasma profiles of healthy women to identify breast carcinoma-associated protein markers...
  10. doi request reprint Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010
    ..We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility...
  11. ncbi request reprint Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..The safety and efficacy data of initial population were updated, with inclusion of additional experience with the same therapy...
  12. ncbi request reprint Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
  13. ncbi request reprint Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1459-66. 2006
    ..The aim of the current study was to develop and validate nomograms for predicting residual tumor size and probability of a patient becoming eligible for breast conservation surgery after NACT...
  14. ncbi request reprint Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:499-506. 2004
    ....
  15. doi request reprint Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  16. ncbi request reprint Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  17. pmc Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  18. pmc Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    Cornelia Liedtke
    DPhil, Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:3185-91. 2009
    ....
  19. pmc PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
    ..In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer...
  20. ncbi request reprint The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  21. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  22. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  23. doi request reprint Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers
    Charles Coutant
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 17:2591-601. 2011
    ..We hypothesized that p53 mutations may lead to different transcriptional changes and carry different prognostic value in these two different types of cancers...
  24. ncbi request reprint Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  25. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  26. pmc Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  27. ncbi request reprint Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  28. ncbi request reprint Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
    W Fraser Symmans
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:4414-22. 2007
    ..To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response...
  29. pmc Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:932-8. 2011
    ..The goal of this study was to determine the impact of disease progression during NCT on surgical management...
  30. ncbi request reprint Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1365-73. 2004
    ..In the current study, the authors investigated the contribution of assessing tumor cellularity in the pathologic evaluation of response to chemotherapy...
  31. ncbi request reprint Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
    Lajos Pusztai
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 009, USA
    Clin Cancer Res 9:2406-15. 2003
    ....
  32. ncbi request reprint DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Biochim Biophys Acta 1766:197-204. 2006
    ..Next, we will compare advantages and limitations of cohort-based and case-control studies. The choice of end-point to discriminate between sensitive and resistant patients will also be examined...
  33. ncbi request reprint Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  34. doi request reprint Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  35. doi request reprint Current status of prognostic profiling in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Oncologist 13:350-60. 2008
    ....
  36. ncbi request reprint Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 13:6080-6. 2007
    ..We examined if supervised analysis of gene expression data from phase II studies could identify HER-2 overexpression as a predictor of response to trastuzumab...
  37. ncbi request reprint Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer
    Florentia Peintinger
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4078-82. 2007
    ..We examined whether the response predicted by a 30-gene pharmacogenomic test correlated with the residual cancer burden (RCB) after preoperative chemotherapy with paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide (T/FAC)...
  38. doi request reprint Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer
    Takayuki Iwamoto
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Natl Cancer Inst 103:264-72. 2011
    ..We hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers...
  39. ncbi request reprint Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1337-42. 2004
    ..We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer...
  40. ncbi request reprint Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5652-9. 2003
    ....
  41. ncbi request reprint Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
    Fan Zhang
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1758-65. 2003
    ..The objective of this study was to determine whether HER-2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma...
  42. pmc Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology, Systems Biology, Biostatistics, Surgical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1109-19. 2012
    ..To examine gene expression differences between pre- and post-neoadjuvant systemic therapy (NST) specimens of breast cancers and identify biologic changers that may lead to new therapeutic insights...
  43. pmc Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 125:785-95. 2011
    ..IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC...
  44. doi request reprint Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers
    Catherine M Kelly
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:5161-7. 2010
    ..The authors hypothesized that the test is ordered when clinicopathological variables yield equivocal risk estimates. The current study also showed how often the test clarifies clinically ambiguous risk status...
  45. pmc Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer
    Judy C Boughey
    Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 244:464-70. 2006
    ..To determine the effect of preoperative chemotherapy on the volume of tissue excised and the number of breast operations in patients undergoing breast-conserving therapy (BCT)...
  46. pmc High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients
    Ashley M Holder
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA
    Breast Cancer Res Treat 137:319-27. 2013
    ..Future studies are needed to define the role of SCD1 in the malignant phenotype of breast cancer and to evaluate the potential for SCD1 as a therapeutic target...
  47. doi request reprint Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
    Takayuki Iwamoto
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 30:729-34. 2012
    ....
  48. doi request reprint Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
    Christine Y Shiang
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, P O Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 123:747-55. 2010
    ..These findings suggest that FGFR-1 amplification or protein overexpression in breast cancers may be an indicator for brivanib treatment, where it may have direct anti-proliferative effects in addition to its' anti-angiogenic effects...
  49. pmc Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
    Adel Tabchy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 16:5351-61. 2010
    ..We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms...
  50. pmc Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010
    ..In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression...
  51. ncbi request reprint Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:258-63. 2004
    ..The objective of the current study was to determine whether her-2 amplification was associated with a pathologic response to preoperative chemotherapy with taxanes in patients with early-stage breast carcinoma...
  52. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  53. ncbi request reprint Molecular classification of breast cancer: limitations and potential
    Lajos Pusztai
    D Phil, University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit1354, PO Box 301439, Houston, Texas 77230 1439, USA
    Oncologist 11:868-77. 2006
    ..To provide context for this discussion, we also briefly examine the performance of estrogen receptor immunohistochemistry, which represents an essential part of the routine diagnostic workup for all breast cancer patients...
  54. doi request reprint First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
    Takayuki Iwamoto
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77230 1439, USA
    Breast Cancer Res Treat 130:155-64. 2011
    ..First-generation prognostic-gene signatures predict both chemotherapy response and long-term survival. When multiple predictors are applied to the same case discordant risk prediction frequently occurs...
  55. doi request reprint Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer
    Olivier Graesslin
    FACP, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 1354, Houston, TX 77030, USA
    J Clin Oncol 28:2032-7. 2010
    ..Selection of an enriched patient population at high risk for brain metastasis will facilitate the design of trials aiming at its prevention...
  56. ncbi request reprint Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  57. doi request reprint Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  58. ncbi request reprint Optimizing outcomes in HER2-positive breast cancer: the molecular rationale
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center Houston, Texas 77030, USA
    Oncology (Williston Park) 19:5-16. 2005
    ..Optimizing the use of therapies that target HER2 signaling will lead to further advances in the treatment of breast cancer...
  59. pmc Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
    Banu Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    J Clin Oncol 29:3739-46. 2011
    ....
  60. ncbi request reprint Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:682-91. 2005
    ....
  61. ncbi request reprint Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  62. doi request reprint Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer
    Shivani S Shinde
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4933-43. 2010
    ....
  63. ncbi request reprint Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cytokine 25:94-102. 2004
    ..The objective of this study was to assess changes in plasma levels of interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha during chemotherapy and to correlate these changes with musculoskeletal symptoms...
  64. doi request reprint Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis
    Xiaohong Leng
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Res 69:8579-84. 2009
    ..Our results suggest that inhibition of LCN2 function by an inhibitory monoclonal antibody has potential for breast cancer therapy, particularly by interfering with metastasis in aggressive types of breast cancer...
  65. ncbi request reprint Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  66. ncbi request reprint Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3249-54. 2003
    ..We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer...
  67. ncbi request reprint Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 24:187-91. 2006
    ....
  68. doi request reprint Preoperative systemic chemotherapy and pathologic assessment of response
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, P O Box 301439, Houston, TX 77230 1439, USA
    Pathol Oncol Res 14:169-71. 2008
    ..Each component contributes meaningful pathologic information and can be obtained using routine pathologic materials and methods of interpretation that could easily be implemented in routine diagnostic practice...
  69. ncbi request reprint Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Drug Resist Updat 7:325-31. 2004
    ..Perhaps, the most important challenge is to prospectively design and conduct validation trials that demonstrate clinical utility by showing improved patient outcomes with the use of a proposed new test...
  70. ncbi request reprint Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Adv Exp Med Biol 587:233-49. 2006
  71. ncbi request reprint Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Nat Clin Pract Oncol 3:621-32. 2006
    ..This Review describes the current limitations and future promises of gene-expression-based molecular classification of breast cancer and how it might impact on selection of adjuvant therapy for individual patients...
  72. ncbi request reprint Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Pharm Res 23:1951-8. 2006
    ....
  73. ncbi request reprint Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
    Yun Gong
    University of Texas, Department of Pathology, Anderson Cancer Center, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Pharmacogenomics 8:1359-68. 2007
    ..This review focuses on the recent progression in feasibility and reliability of gene-expression microarrays in identifying new prognostic and predictive indicators of breast cancer...
  74. ncbi request reprint Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..The purpose of this study was to analyze global gene expression changes in serial tumor core biopsy specimens taken during neoadjuvant chemotherapy for primary breast cancer...
  75. ncbi request reprint Estrogen receptors and distinct patterns of breast cancer relapse
    Kenneth R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4409, USA
    Breast Cancer Res Treat 78:105-18. 2003
    ..We conducted an analysis of prospectively collected data to compare the clinical behavior of ER-negative versus ER-positive tumors with respect to rates and sites of recurrence...
  76. ncbi request reprint Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  77. ncbi request reprint Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 1:44-50. 2004
    ..Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction...
  78. ncbi request reprint Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Breast Cancer 12:73-85. 2005
    ..D. Anderson Cancer Center. This manuscript is based on a presentation that was given during the Presidential Symposium of the annual meeting of the Japanese Breast Cancer Society in 2004...
  79. ncbi request reprint Reproducibility of gene expression signature-based predictions in replicate experiments
    Keith Anderson
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 12:1721-7. 2006
    ....
  80. ncbi request reprint Gene expression profiling of primary breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 7:38-44. 2005
    ..The first multigene predictor of prognosis after tamoxifen therapy is already commercially available in the United States. This article reviews recent advances in the clinical application of this technique to breast cancer...
  81. ncbi request reprint Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 141:148-53. 2003
    ..Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics...
  82. ncbi request reprint The use of microarray technology in the management of breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 5:193-4, 197. 2007
  83. pmc An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Katherine Stemke-Hale
    Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer Res 68:6084-91. 2008
    ..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer...
  84. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
    ..We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer...
  85. ncbi request reprint Breast cancer biomarkers and molecular medicine: part II
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, MC 80 Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Expert Rev Mol Diagn 4:169-88. 2004
    ..The second section will consider the prediction of therapy response using the techniques of pharmacogenetics and pharmacogenomics...
  86. ncbi request reprint Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
    Luca Gianni
    Medical Oncology, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 23:7265-77. 2005
    ..We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk...
  87. doi request reprint Commercialized multigene predictors of clinical outcome for breast cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Oncologist 13:477-93. 2008
    ..A number of other assays have specific predictive goals that are most often focused on the efficacy of tamoxifen in ER-positive patients, such as the two-gene ratio test and the cytochrome P450 CYP2D6 genotyping assay...
  88. doi request reprint Lost in translation--prognostic signatures for breast cancer
    Lajos Pusztai
    Nat Clin Pract Oncol 5:363. 2008
  89. doi request reprint Research issues affecting preoperative systemic therapy for operable breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
    J Clin Oncol 26:806-13. 2008
    ..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care...
  90. ncbi request reprint Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007
    ..Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies...
  91. ncbi request reprint Targeted therapies for cancer 2004
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 122:598-609. 2004
    ....
  92. ncbi request reprint Targeted therapy in breast cancer: the HER-2/neu gene and protein
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Mol Cell Proteomics 3:379-98. 2004
    ..The review will also evaluate the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response...
  93. ncbi request reprint Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    Fabrice Andre
    Breast Cancer Unit and Translational Research Unit, UPRES03535, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:2061-7. 2007
    ..A molecular marker may be prognostic of outcome or predictive of response to therapy, or a combination of both...
  94. pmc Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
    ..Multigenic predictors were designed by selecting probe sets highly ranked in their predictions and tested using several validation sets...